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Abstract
Longitudinal studies are defining progressive alterations to the immune system associated with
increased mortality in the very elderly. Many of these changes are exacerbated by or even caused
by chronic T cell stimulation by persistent antigen, particularly from Cytomegalovirus. The
composition of T cell subsets, their functional integrity and representation in the repertoire are all
markedly influenced by age and by CMV. How these findings relate to epidemiological, functional,
genetic, genomic and proteomic studies of human T cell immunosenescence was the subject of
intense debate at an international conference held just before Christmas 2005 in the Black Forest.
Background
This conference was the final meeting of the EU project "T-
Cells in Aging", T-CIA [1]. T-CIA brought 8 European
centers together for 3 years to study T cell immunosenes-
cence in clonal models in vitro and ex vivo in the elderly.
The former focused on long-term cultures of T cell clones
(TCC), the latter on longitudinal studies of the very eld-
erly. This work formed the core of the data presented at
the meeting in Freudenstadt-Lauterbad, 13–16 December,
2005. The T-CIA project, coordinated by Graham Pawelec
(Tübingen University) evolved from the earlier EU-sup-
ported networking projects EUCAMBIS and ImAginE, and
has investigated human T-cell immunosenescence in vivo
end in vitro with the aim of increasing the understanding
of immune ageing and laying the preclinical groundwork
for rational intervention.
Senescence of clonotypic immunity is thought to be prin-
cipally a result of the declining effectiveness of T cells.
Lifelong exposure to chronic antigenic load is the major
driving force of immunosenescence, impacting on human
lifespan by reducing the number of naïve antigen-non-
experienced T cells, and, simultaneously, filling the
immunological space with expanded clones of memory
and effector, antigen-experienced T cells [2]. Gradually,
the T-cell population shifts to a lower ratio of naïve to
memory cells, the thymus generates fewer naïve T cells
with age and those T cells remaining, especially the CD8+
subset, also show increased oligoclonality with age. Thus,
the repertoire of cells available to respond to antigenic
challenge from previously unencountered pathogens is
shrinking. In addition, older individuals commonly pos-
sess memory cells carrying a single T cell receptor, i.e. they
represent clonal expansions. Thus, the memory cells from
old individuals might recognize a limited set of antigens
despite being plentiful in number. Many of the clonal
expansions crowding an elderly person's immune system
result from previous infections by persistent viruses,
resulting in the presence of many CD8+ cells specific for a
limited number of epitopes of herpes viruses: in some
individuals more than 10% of peripheral CD8 cells react
against a single CMV epitope [3]. Here, then, there is
potential for intervention, both prophylactic (vaccina-
tion), therapeutic (anti-virals) and immunologic (dele-
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was suggested by Katsuiku Hirokawa (Tokyo Medical &
Dental University) who proposed banking peripheral T
cells from younger individuals, depleting their dysfunc-
tional cells in later life, and replenishing from the frozen
bank of young T cells. This type of "mini-transplant" is
standard procedure in cancer therapy. Memory T cells usu-
ally carry the CD28 surface protein, which helps stimulate
the cells to divide when antigen is present. But old mem-
ory cells tend to lose CD28 and, as a result, multiply less
robustly when exposed to antigen than do younger cells
[3]. Here, therefore, is another opportunity for interven-
tion: cause re-upregulation of CD28, either by gene ther-
apy or application of cytokines such as interleukin (IL)-12
or antibodies neutralising tumor necrosis factor (TNF)-α.
As a consequence of the above events, if unchecked, T and
B immunosenescence and, likely, mortality and morbid-
ity, will occur earlier in people that have been exposed to
an antigenic overload (due to chronic infections). The
opposite situation may apply to people exposed to a lower
antigenic load and/or with an appropriate immunoge-
netic background. This implies that the ability of our
immune system is progressively worn down by the need
to maintain immunosurveillance against persistent path-
ogens or other sources of antigen, such as cancer [4].
Cytomegalovirus (CMV)
For the reasons discussed above, a good part of the meet-
ing, like the elderly immune system, was obsessed with
CMV. Paul Moss (University of Birmingham) showed
that cytomegalovirus infection at any stage in life adds
more age to the ageing process with respect to the naïve
compartment. Indeed, the immune response to CMV can
account for around 25% of all the clonal CD8+ T cell pop-
ulations that are known to accumulate with ageing. Con-
comitantly, the absolute T cell count is increased by 20%
in elderly donors who are CMV-positive compared with
CMV sero-negative. This correlates with the absolute
count of CD8+ T cells doubling in the CMV-seropositive
cohort and with the CD8+CD28- subset dramatically
increased 5-fold. Because CMV infection results in such
strong T cell responses, methods to control infection and
to prevent reactivation through vaccination might be ben-
eficial [5]. According to the old adage "know your enemy"
maximising our information on CMV-immune system
interactions might also facilitate control of the beast. Ste-
fan Stevanovic (University of Tübingen) investigated
CMV-specific T cell responses in a large number of healthy
donors of different human leukocyte antigen (HLA) types
and found that as previously reported, almost all HLA-
A*01-, A*02-, and B*07- positive individuals had TCR
specific for a limkited range of immunodominant
epitopes. However, people with other HLA-allotypes did
not mediate such immunodominant responses, suggest-
ing that control by vaccination with a limited number of
epitopes may be more complicated [6].
In the elderly, Rafael Solana (University of Cordoba)
observed higher percentages of CMV-specific CD8 effector
memory cells, and showed that it was these cells which
predominantly expressed enhanced levels of HLA class-I-
specific and non-specific NK receptors [7]. These results
suggest that interactions usually occurring within the
innate immune system will need to be taken into count
when considering CMV control strategies. Paolo Sansoni
(University of Parma) confirmed that age-associated
CD8+ T clonal expansion could be related to increased fre-
quency of CMV infection. In particular, CD28- T cells
accumulate, with age, only in seropositive subjects both
within CD4+ and CD8+ cells while reduction of naïve T
cells is more profound among CMV-seropositive subjects
within CD8+ T cells. He also found that IFN-γ -producing
cells specific for at least one immunodominant CMV pro-
tein within CD8+ or CD4+ subsets increase with age [8].
These results indicate that while attention has focussed on
the larger clonal expansions seen in CD8 cells, effects on
CD4 cells are also likely to be critical in shaping the eld-
erly immune response.
Apoptosis
Aging is associated with a paradox of increased autoim-
munity, yet also with a state of immunodeficiency, with
an increased frequency of infections and cancer. Among
immune functions, a decline in T-cell functions during
aging predominates. In aging, there is an increased pro-
duction of TNF-α and decreased naive CD8+ T cells
whereas memory CD8+T cells are increased, under the
influence of CMV as discussed above. Sudhir Gupta (Uni-
versity of California) reported that naïve and central
memory (TCM) CD8+ T cells are decreased in ageing,
whereas the CD45RA- effector memory (TEM) and
CD45RA+ effector memory (TEMRA) CD8+ T cells are
increased. The hypothesis is that the alterations in naïve
and CD8+T memory cells in ageing may be due to their
differential sensitivity to apoptosis. Naive and TCM
CD8+T cells from old donors are significantly more sus-
ceptible to TNF-α-induced apoptosis as compared to
naïve and TCM from young subjects, whereas TEM and
TEMRA CD8+ T cells are resistant to apoptosis in both
young and aged subjects. Furthermore, in ageing, apopto-
sis in TCM CD8+ T cells, as defined by CCR7 or CD62L
expression, was greater as compared to naive CD8+ T cells.
It was also observed that the increased apoptosis in aged
naive and TCM CD8+ T cells was associated with
increased cleavage of both caspase-8 and caspase-3 as
compared to young subjects [9,10]. This kind of increased
apoptosis of naïve and central memory T cells may con-
tribute to T cell immunodeficiency associated with
human ageing. In contrast, abnormal phagocytosis ofPage 2 of 6
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response by dendritic cells may explain the paradoxical
increased inflammation associated with human ageing.
Modulation of these processes may therefore also offer
scope for intervention.
Genetics
The pathogenic burden, to which an individual has been
or is exposed, may be linked to levels of chronic inflam-
mation and to increased risk of age-related diseases. This
will be influenced by genetic factors affecting the capacity
of the host to control the pathogen-induced inflammatory
response. Calogero Caruso (University of Palermo) sug-
gested that within the inflammatory network, the most
important node of the net is represented by CD14, the
main receptor for Gram-negative endotoxin, and its co-
receptor, TLR4, responsible for activating intracellular sig-
nalling pathways. Several functional polymorphisms have
been described in these genes associated with age-related
disease. Thus, the intensity of the genetically-determined
inflammatory response against pathogens or their anti-
gens might play a major role in determining the magni-
tude of inflammation and subsequent clinical outcome.
The presence of gene polymorphisms with pro-inflamma-
tory associations may fuel the inflammatory response of
macrophages to gram-negative infection, promoting pro-
inflammatory status and clinical setting of the inflamma-
tory diseases [11,12]. This implies that people genetically
predisposed to a weak inflammatory activity have less risk
of developing age-related diseases and genetic polymor-
phisms responsible for a low inflammatory response
might therefore result in an increased chance of a long
life-span in a modern environment with a reduced patho-
gen burden.
Elisavetta Naumova (University of Sofia) studying the
Bulgarian population focused on the relevance of HLA
and cytokine genotype profiling as predictors of successful
ageing. The analysis showed statistically significantly
increased frequencies in elderly individuals and in fami-
lies with long-lived members of HLA haplotypes such as
DRB*11 and DRB*16. However, the pro-inflammatory
cytokine gene polymorphisms for IL-2, IL-6, IFN-γ did not
differ significantly between elderly and controls, but dif-
ferences were observed for IL-10, TGF-β, and TNF-α genes,
supporting a role of HLA and cytokine genes in successful
ageing [13].
Another factor with a genetic basis discussed in this ses-
sion, which could be contributing to T cell immunosenes-
cence and chronic inflammation in the elderly, is the
dysregulation of zinc homeostasis (Marco Malavolta,
INRCA, Ancona). Preliminary results from the EU ZIN-
CAGE Project, indicate that zinc dyshomeostasis, charac-
terized by high levels of expression of metallothioneins
(MT) associated with plasma zinc deficiency and impaired
release of zinc at the intracellular level, may occur mostly
in aged T cells of subjects carrying the C allele of the 647
A/C MT1A SNP, especially when associated with a pro-
inflammatory cytokine profile. In contrast, carriers of the
A allele, perhaps through a better regulation of zinc home-
ostasis, have a greater likelihood of longer life [14]. Care-
ful zinc supplementation my therefore also represent a
possible intervention to help maintain immunological
integrity, an approach that the ZINCAGE project is cur-
rently testing.
Daniel Remondini (Bologna University) presented data
on T-cell profiling over lifespan in humans, suggesting a
possible global response of gene activity in ageing.
In vivo correlates
Although the immune system exhibits profound age-
related changes, it has been suggested that old individuals
frequently do retain some capacity to produce fully func-
tional new T cells. However, how we can define naïve cells
in the elderly? This question [15] was addressed by Beat-
rix Grubeck-Loebenstein (Institute of Biomedical Age-
ing Research, Innsbruck), who reported her quest for
truly naïve cells in the elderly within a theoretically naïve
population (as defined by co-expression of the surface
moleculesCD8+ CD28+ CD45RA+ CD62L+). What
emerged is that these "naïve cells" had shorter telomeres
and a more limited antigen receptor repertoire in the old
than in the young. This implies that "naïve cells" in the
elderly have undergone considerable division and may be
considered "aged cells" despite being phenotypically
naïve. It also raises the question as to whether these mark-
ers of "naïve" cells are reliable.
It is becoming clear that external factors like infections
occurring early in life may affect T cell functions in the eld-
erly, first and foremost, CMV infection. There are, how-
ever, also non-infectious diseases recognized as associated
with impaired functionality of CD4+ T cells and known to
significantly shorten life span. Among them, Jacek M.
Witkowski (Medical University of Gdansk) suggested
that rheumatoid arthritis (RA) is associated with acceler-
ated ageing of CD4+ T cells. Thus, physiological ageing-
and RA-associated characteristics of CD4+ lymphocytes
display marked similarities and include identical patterns
of change of dynamic parameters of proliferation stem-
ming from similar underlying mechanisms, like increase
expression of cyclin D1 and decreased expression of the
CD28 co-stimulatory molecule. Also in two other "life-
shortening" diseases, systemic lupus erythematosus and
Alzheimer disease, the CD4+ cells are primed for activa-
tion, showing a decreased duration of the G0→G1 transi-
tion time, yet associated with a reduced ability to produce
viable progeny [16].Page 3 of 6
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cially and logistically challenging, but yield uniquely
informative data. The OCTO/NONA studies described by
Anders Wikby (Jönköping University) resulted in the
development of the concept of an "Immune Risk Profile
"(IRP) in population-based samples of individuals aged
86–99 years. The factors studied now include analysis of T
cell subsets, inflammatory markers, virus serology,
cytokines, DNA damage, TCR clonotype mapping, and
functional and phenotypic analysis of virus-specific CD8+
cells by HLA/peptide multimers. These studies emphasize
the paramount importance of multi-disciplinary collabo-
ration between many different laboratories specialised in
different areas, as illustrated by the T-CIA project [17].
Mechanism
The elderly possess more or less the same numbers of
peripheral T cells as the young, but as we have seen above,
of very different subset and clonal composition. In addi-
tion, age-associated alterations on a per-cell basis contrib-
ute to immunosenescence, as illustrated by altered signal
transduction pathways and processes in cells from old
donors. Tamas Fulop (University of Sherbrooke, Can-
ada) gave a general overview on the mechanisms of signal
transduction through the T cell receptor, remarking on the
key role played by lipid rafts in the formation of the initial
complex of signal transduction for T-cell activation. Age-
related changes in the cell membrane and specifically
impacting on lipid rafts, (cholesterol content, fluidity and
signalling molecule composition) may help to explain the
severe impairment of CD4+ T-cell signalling observed in
ageing, taking also into account that CD4+ T-cell activa-
tion completely relies on of lipid raft polarization. Fur-
thermore, a different signalling of the CD28 co-receptor
has been shown for the first time among CD4+ and CD8+
T cells from elderly subjects, independent of the measura-
ble CD28 receptor number [19]. This suggests that the
physico-chemical properties of the membrane influences
more the signalling of a receptor thanthe receptor number
per se." [18-20]. In stark contrast, and clearly something
that must always be considered when thinking about the
emerging differences between CD4 and CD8 cells, activa-
tion of the latter is independent of lipid raft polarization.
Along the same lines, Anis Larbi (University of Tubigen)
compared membrane fluidity and cholesterol content,
two key parameters in lipid raft function and conse-
quently TCR signalling, in T cell clones (TCC) derived
from CD34+ progenitor cells, young adult donors or cen-
tenarians. Cholesterol content decreased while mem-
brane fluidity increased during "in vitro" ageing, but
stimulation via the TCR and CD28 led to different phos-
phorylation patterns depending more on the age of the
donor than the in vitro age of the clones. These results
possibly suggest that TCC may represent intrinsically
divergent properties of the donor cells rather than culture-
induced changes [18]. However, they also show that inter-
vention using lipids, either injected or ingested, may
result in some degree of immune modulation of potential
benefit to the elderly. Further studies on signal transduc-
tion, as related to telomerase expression in CD8+ T cells,
were presented by Fiona Plunkett (University College,
London). Investigating telomere length, telomerase
expression, proliferative capacity, and co-stimulatory
receptor expression in the various CD8+ CD28/CD27
subpopulations, she showed that CD8+CD28-CD27- T
cells have short telomeres and a decreased capacity to up-
regulate telomerase in the absence of exogenous cytokines
such as IL-2 and IL-15. Using chimeric receptors, it was
also shown that up-regulation of telomerase expression in
CD8+ T cells can be achieved through other co-stimula-
tory molecules, such as CD27, CD137 and ICOS, and not
only via CD28. This suggests that CD8+CD28-CD27- T
cells could still function if given appropriate alternative
costimulation and a conducive cytokine milieu for their
full activation [21].
Not only does T-helper and cytototoxic cell activation at
the single cell level change with ageing, but the frequency
and behaviour of regulatory T cells is attracting increased
attention once more, also in the context of ageing. The
maintenance of immunity has to be balanced with appro-
priate controls to prevent non-specific inflammation and
immunopathology, which it is thought are major prob-
lems in ageing. Arne Akbar (University College, Lon-
don), studying the susceptibility to apoptosis, telomere
length, turnover and clonal composition of the regulatory
population, reported that CD4+CD25+ T-regulatory cells
(T-regs) are generated continuously, most likely by differ-
entiation of CD4+ T-cells in the presence of regulatory
cues [23]. These concepts on the mechanisms and
dynamic contributing to peripheral tolerance by
CD4+CD25+ T-regs, have important implications for the
design of therapeutic strategies involving generation and
use of CD4CD25+ T-regs in autoimmune and inflamma-
tory diseases. Clearly, their manipulation in ageing will
also be of great potential benefit.
Given the difficulty of finding (or defining) naïve cells in
the elderly, and given the well-know phenomenon of
thymic involution, one focus of attention for researchers
interested in immunosenescence must be the thymus
itself. As discussed by Richard Aspinall (Imperial Col-
lege, London) interventionist therapies, based around IL-
7, aimed at rejuvenating the thymus to the size and cellu-
larity seen during early life and restoring thymic output,
may be an attractive avenue to explore. In particular, treat-
ment with a CCR9/IL-7 fusion protein, which retains its
IL-7 activity, seems particularly intriguing because it dis-
plays an increased ability to target only the thymus, thus
avoiding any side effects of high-dose IL 7 (which may bePage 4 of 6
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tein responded better to influenza infection (in terms of
CD8 activation, viral load in the lung and change in
weight) than IL-7 or untreated animals [22].
Even given the possibility of enhancing naïve T cell gener-
ation and improving signal transduction for activation,
genomic instability and repair mechanisms of vigorously
proliferating cells remains a major concern. Alexander
Burkle (University of Constance), reviewed the role of
poly(ADP-ribosyl)ation and poly(ADP-ribose) polymer-
ase-1 (PARP-1) in retarding the accumulation of DNA
damage and in slowing down the rate of ageing [24].
Molecular genetic approaches to modulate poly(ADP-
rybosyl)ation and an innovative method to assess
poly(ADP-ribosyl)ation capacity by flow cytometry will
facilitate study of and intervention in this critical gate-
keeping system. Repair mechanisms in T cells were also
addressed by Erminia Mariani and Simona Neri (Univer-
sity of Bologna), who investigated the mismatch repair
system (MMR) in T CC derived from hematopoietic stem
cells and peripheral T cells from young, old and centenar-
ian donors. By analysing mutations in particular non-cod-
ing regions (microsatellites), they observed that in vitro
replication increased genomic instability and altered
MMR gene expression especially markedly in CD34+ cell-
derived clones. This can be seen also in TCC in relation to
donor age, suggesting a reduced efficiency of the MMR
system during in vitro ageing [25]. Improving DNA repair
mechanisms would obviously be a general benefit, not
only in ageing but also in cancer and other diseases.
The challenge to find key modulators of immunosenes-
cence and ageing was addressed by Dawn Mazzatti (Uni-
lever R&D Colworth, UK) combining genomic and
proteomic investigations on T-lymphocytes isolated from
young and old donors, as well as TCC grown to senes-
cence in vitro. The proteins which were demonstrated to
be differentially expressed in immunosenescence in TCC
following SELDI analysis and further identified by
MALDI/ESI-MS/MS were associated with SELDI peaks at
13–14kDa (identified as Histone H2B.q, H2A.5, H2A.q,
H2B, and H2B.1) and 8.3–8.5kDa (Tetraubiquitin, chain
B and Ubiquitin mutant). Genes found to be differentially
expressed in human ex vivo samples during ageing
belonged to variety of functional processes which were
analysed by Ingenuity Pathway analysis software. These
include metabolism, cytoskeleton remodelling, histone
organisation, cell-cell communication, signalling and
protein degradation. All these gene/proteins might consti-
tute possible targets to ameliorate immunosenescence in
the near future. In the meantime, a more direct approach
with different antioxidants/ROS scavengers aimed at alle-
viating the dangerous effects of reactive oxygen species
(ROS) on TCC was applied by Yvonne Barnett (Notting-
ham Trent University, Nottingham). She found that car-
nosine and N-tert-butyl-α-phenylnitrone (PBN) extended
the lifespan of TCC, at the same time as reducing DNA
damage. Paradoxically, and contrary to expectations, a
superoxide dismutase mimetic (EUK-134) and reduced
oxygen tension (6%) culture conditions shortened the
lifespan and proliferative capacity of TCCs, despite pro-
tecting against DNA damage [26]. These results suggests
that better protection against free radicals might be useful
to achieve functional longevity extension of human TCCs,
but also that functional mechanisms requiring free radical
production suggest complexity of applying anti-oxidant
approaches in living cells.
Conclusion
Improving our understanding of immune ageing is a nec-
essary step towards identifying ways to ameliorate and
treat the underlying causes of immunosenescence. Pres-
ently, there are very few treatments that seem both clini-
cally applicable and efficacious, but some of the
preclinical rationales for interventions discussed at this T-
CIA final conference, some of which are mentioned
above, may open promising perspectives. Application of
most of the possible, but untested, interventions in the
elderly is, however, fraught with ethical as well as medical
difficulties in the case of people who are not overtly sick.
These, as well as the scientific problems, now require dis-
cussion as a matter of priority.
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